RU2012117563A - Режим дозирования модулятора рецептора s1p - Google Patents

Режим дозирования модулятора рецептора s1p Download PDF

Info

Publication number
RU2012117563A
RU2012117563A RU2012117563/15A RU2012117563A RU2012117563A RU 2012117563 A RU2012117563 A RU 2012117563A RU 2012117563/15 A RU2012117563/15 A RU 2012117563/15A RU 2012117563 A RU2012117563 A RU 2012117563A RU 2012117563 A RU2012117563 A RU 2012117563A
Authority
RU
Russia
Prior art keywords
agonist
patient
receptor
modulator
administration
Prior art date
Application number
RU2012117563/15A
Other languages
English (en)
Russian (ru)
Inventor
Крейг БУЛТОН
Паскаль БЮРТЕН
Оливье Давид
Ана ДЕ-ВЕРА
Томас Дюмортье
Айрин ХАНТ
Роберт Шмоудер
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2012117563(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2012117563A publication Critical patent/RU2012117563A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/021—Measuring pressure in heart or blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/024—Measuring pulse rate or heart rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/444—Evaluating skin marks, e.g. mole, nevi, tumour, scar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4833—Assessment of subject's compliance to treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
RU2012117563/15A 2009-09-29 2010-09-20 Режим дозирования модулятора рецептора s1p RU2012117563A (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US24670609P 2009-09-29 2009-09-29
US61/246,706 2009-09-29
US25832909P 2009-11-05 2009-11-05
US61/258,329 2009-11-05
US30799210P 2010-02-25 2010-02-25
US61/307,992 2010-02-25
US35202910P 2010-06-07 2010-06-07
US61/352,029 2010-06-07
PCT/US2010/049441 WO2011041146A2 (en) 2009-09-29 2010-09-20 Dosage regimen of an s1p receptor modulator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2018118645A Division RU2776152C2 (ru) 2009-09-29 2010-09-20 Режим дозирования модулятора рецептора s1p

Publications (1)

Publication Number Publication Date
RU2012117563A true RU2012117563A (ru) 2013-11-10

Family

ID=43759693

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012117563/15A RU2012117563A (ru) 2009-09-29 2010-09-20 Режим дозирования модулятора рецептора s1p

Country Status (18)

Country Link
US (9) US20120264719A1 (https=)
EP (4) EP3061449A1 (https=)
JP (5) JP2013505983A (https=)
KR (1) KR20120083442A (https=)
CN (2) CN103933570A (https=)
AU (2) AU2010101513B4 (https=)
BR (1) BR112012006957A2 (https=)
CA (2) CA2773330C (https=)
IL (2) IL218486A0 (https=)
MA (1) MA33691B1 (https=)
MX (1) MX2012003740A (https=)
NZ (1) NZ598534A (https=)
PH (2) PH12012500520A1 (https=)
RU (1) RU2012117563A (https=)
SG (4) SG10201913361RA (https=)
TN (1) TN2012000104A1 (https=)
WO (1) WO2011041146A2 (https=)
ZA (2) ZA201201678B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598534A (en) * 2009-09-29 2014-03-28 Novartis Ag Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
JP6111202B2 (ja) 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
EP3502236B1 (en) * 2011-02-18 2023-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
CA2851525A1 (en) * 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
BR112014009141A8 (pt) * 2011-10-21 2017-06-20 Novartis Ag regime de dosagem para um modulador ou agonista do receptor s1p
BR112015020140A8 (pt) * 2013-04-04 2019-11-19 Novartis Ag ácido 1-{4-[1-(4-ciclo-hexil-3-trifluorometil-benziloxi-imino)-etil]-2-etil-benzil}-azetidina-3-carboxílico, seus usos e combinação farmacêutica
EP3129020A1 (en) * 2014-04-10 2017-02-15 Novartis AG S1p modulator immediate release dosage regimen
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
CN116784795A (zh) 2017-11-30 2023-09-22 思维有限公司 用于评估与多发性硬化症相关的神经功能受损的方法
WO2020214513A1 (en) * 2019-04-17 2020-10-22 Pear Therapeutics, Inc. Electronic devices and methods for treatment of depressive symptoms, depressive disorders utilizing digital therapies
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
WO2021158847A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158845A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158843A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158841A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158839A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
WO2021158844A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Treatment and dosing regimen for s1p receptor modulator
EP4164605A4 (en) * 2020-06-11 2024-06-19 The Trustees of Columbia University in the City of New York METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MYOPIA WITH FINGOLIMOD, A SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR AND DERIVATIVES THEREOF
CN119997878A (zh) * 2022-07-28 2025-05-13 思维有限公司 使用视觉刺激、药物或治疗来鉴定疾病特有的眼球运动模式

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231560B1 (en) * 1999-02-10 2001-05-15 Baxter International Inc Method and apparatus for automatically controlling the level of medication
PT1505959E (pt) 2002-05-16 2009-02-05 Novartis Ag Utilização de agentes de ligação do receptor edg em cancro
GB0211261D0 (en) * 2002-05-16 2002-06-26 Novartis Ag Organic compounds
ES2294480T3 (es) * 2003-03-14 2008-04-01 Agi Therapeutics Research Limited Tratamiento de afecciones instestinales con n-2,3,3-tetrametilbiciclo(2.1.1)heptan-2-amina.
EP1644367B1 (en) 2003-05-19 2015-10-14 Novartis AG Immunosuppressant compounds and compositions
AU2004271804B2 (en) 2003-09-12 2011-01-06 Newron Sweden Ab Treatment of disorders of the nervous system
US7127355B2 (en) * 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
KR20070085465A (ko) 2004-11-29 2007-08-27 노파르티스 아게 Ｓ１ｐ 수용체 효능제의 투여 용법
JP2007061274A (ja) * 2005-08-30 2007-03-15 Transcutaneous Technologies Inc センサからの副作用情報による投薬停止システムを備えたイオントフォレーシス装置
EP1905434A1 (en) 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
JP2011525189A (ja) 2008-06-20 2011-09-15 ノバルティス アーゲー 多発性硬化症を治療するための小児科の組成物
TW201028143A (en) 2008-12-22 2010-08-01 Novartis Ag Dosage regimen for a S1P receptor agonist
NZ598534A (en) * 2009-09-29 2014-03-28 Novartis Ag Dosage regimen of an s1p receptor modulator

Also Published As

Publication number Publication date
EP2482810A2 (en) 2012-08-08
SG10201913361RA (en) 2020-03-30
ZA201404270B (en) 2014-12-23
JP7185426B2 (ja) 2022-12-07
US11759436B2 (en) 2023-09-19
CA3129729A1 (en) 2011-04-07
US20120264719A1 (en) 2012-10-18
CA2773330A1 (en) 2011-04-07
PH12017501495A1 (en) 2018-07-02
JP2020203892A (ja) 2020-12-24
JP2016155840A (ja) 2016-09-01
RU2018118645A3 (https=) 2021-09-13
TN2012000104A1 (en) 2013-09-19
US20140187516A1 (en) 2014-07-03
MX2012003740A (es) 2012-04-30
WO2011041146A3 (en) 2011-06-03
WO2011041146A2 (en) 2011-04-07
US20180263930A1 (en) 2018-09-20
MA33691B1 (fr) 2012-10-01
CN102548579A (zh) 2012-07-04
EP3047848A1 (en) 2016-07-27
RU2018118645A (ru) 2018-11-05
CA2773330C (en) 2021-11-02
US20260053756A1 (en) 2026-02-26
JP2018172401A (ja) 2018-11-08
US10543179B2 (en) 2020-01-28
ZA201201678B (en) 2016-01-27
JP2023093482A (ja) 2023-07-04
NZ598534A (en) 2014-03-28
EP3831371A1 (en) 2021-06-09
EP3061449A1 (en) 2016-08-31
BR112012006957A2 (pt) 2016-06-14
IL250439A0 (en) 2017-03-30
PH12012500520A1 (en) 2012-10-22
JP2013505983A (ja) 2013-02-21
CN103933570A (zh) 2014-07-23
AU2010101513A6 (en) 2014-07-10
SG10201902152XA (en) 2019-04-29
US20200222338A1 (en) 2020-07-16
KR20120083442A (ko) 2012-07-25
US20230086687A1 (en) 2023-03-23
US20160256416A1 (en) 2016-09-08
AU2010101513B4 (en) 2016-05-05
US20170304226A1 (en) 2017-10-26
IL218486A0 (en) 2012-04-30
US20180263929A1 (en) 2018-09-20
AU2010300919A1 (en) 2012-03-22
SG178987A1 (en) 2012-04-27
SG10201406168RA (en) 2014-11-27
AU2010101513A4 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
RU2012117563A (ru) Режим дозирования модулятора рецептора s1p
AU2013295370B2 (en) Use of biotin for the treatment of multiple sclerosis
JP2013505983A5 (https=)
JP2009530385A (ja) うつ病の治療のためのケタミンの鼻内投与
JP2017510607A5 (https=)
Ryu et al. A comparison of retrobulbar block, sub-Tenon block, and topical anesthesia during cataract surgery
JP2008029346A (ja) 糖尿病黄斑症の予防又は治療剤
EA028060B1 (ru) Комбинированная терапия бокового амиотрофического склероза
CN107405335A (zh) 治疗肌萎缩侧索硬化和神经病的方法
Gaffar et al. A case of central diabetes insipidus after ketamine infusion during an external to internal carotid artery bypass
Rylkova et al. Effects of NPY and the specific Y1 receptor agonist [D-His26]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats
Fotuhi et al. The effects of obesity on brain structure and size
TW201320994A (zh) 投藥療程
Şık et al. Intrathecal baclofen use in the management of tetanus related spasm: A case report
Ekbom et al. Effects of midazolam and nitrous oxide on endocrine and metabolic measurements in children
CN112641765B (zh) 丙泊酚的抗疲劳制药用途
RU2556792C1 (ru) Способ анестезии при выполнении операции циклофотокоагуляция у пациентов с синдромом "хронической" боли
RU2498826C1 (ru) Способ лечения больных с черепно-мозговой травмой
JP2026510026A (ja) 糖尿病の対象における変形性関節症の疼痛を処置するための延長放出性トリアムシノロンアセトニド
Klein et al. Treatment Algorithm for Uterine Bleeding in Patients on Mechanical Circulatory Support
US11986458B1 (en) Natural and synthetic andrographolides compounds for the treatment of skeletal muscular dystrophies
RU2655763C2 (ru) Фармацевтическая композиция и способ лечения женских сексуальных дисфункций
RU2317080C1 (ru) Фармакологическая коррекция повышенного симпатического тонуса у пациентов с артериальной гипертензией
WO2026040961A1 (zh) pUDK-HGF注射液的用途
RU2458702C1 (ru) Способ лечения атрофии зрительного нерва у детей раннего возраста